60 Degrees Pharmaceuticals Inc (SXTP) FinancialsSXTP60 Degrees Pharmaceuticals Inc

Evaluating the bottom line, 60 Degrees Pharmaceuticals Inc maintains a gross margin of 27.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1092.41%, while the net margin is -1089.76%. These profitability ratios, combined with a Return on Equity (ROE) of -332.89%, provide a clear picture of how effectively SXTP converts its operational activities into shareholder value.

In the context of the broader market, SXTP competes directly with industry leaders such as ENLV and APVO. With a market capitalization of $2.08M, it holds a significant position in the sector. When comparing efficiency, SXTP's gross margin of 27.32% stands against ENLV's N/A and APVO's N/A. Such benchmarking helps identify whether 60 Degrees Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company reported a 106% year-over-year increase in product revenue for Q2 2026, but still faced a widening net loss from $1.84 million to $2.40 million, indicating challenges in profitability despite revenue growth.